WO2008037746A1 - Pyridooxazepine progesteron receptor modulators - Google Patents
Pyridooxazepine progesteron receptor modulators Download PDFInfo
- Publication number
- WO2008037746A1 WO2008037746A1 PCT/EP2007/060225 EP2007060225W WO2008037746A1 WO 2008037746 A1 WO2008037746 A1 WO 2008037746A1 EP 2007060225 W EP2007060225 W EP 2007060225W WO 2008037746 A1 WO2008037746 A1 WO 2008037746A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- compound according
- pyrido
- dibenzo
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to (czV)-8-fluorodibenzo[/ ⁇ /]pyrido[l,2-d]oxazepine-l-amme derivatives that are modulators of progesterone receptors, to their application in the field of contraception, hormone replacement therapy (HRT) or therapy of gynaecological disorders, as well as adjuvant therapy in cancer and other diseases, and to methods for the making and use of such compounds.
- HRT hormone replacement therapy
- Intracellular receptors are a class of structurally related proteins involved in the regulation of gene transcription. Steroid receptors are a subset of these receptors, including the progesterone receptor (PR), androgen receptor (AR), estrogen receptor (ER), glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). Regulation of a gene requires the intracellular receptor and a corresponding ligand which has the ability to selectively bind to the receptor in a way that affects gene transcription.
- PR progesterone receptor
- AR androgen receptor
- ER estrogen receptor
- GR glucocorticoid receptor
- MR mineralocorticoid receptor
- Progesterone receptor modulators are known to play an important role in the health of women.
- the natural ligand for PR is the steroid hormone progesterone, but synthetic compounds have been made which may also serve as ligands (see e.g. Jones et al, U.S. Patent No. 5688810).
- Progestagens are currently widely used for hormonal contraception and in HRT. Other important clinical applications of progestagens are treatment of gynaecological disorders (e.g. endometriosis, dysmenorrhea, dysfunctional uterine bleeding, severe premenstrual syndrome), breast cancer, hot flushes and mood disorders, and luteal support during IVF. In addition, they are applied in combination with other hormones and/or other therapies including, without limitation, chemotherapeutic agents such as cytotoxic and cytostatic agents, immunological modifiers such as interferons and interleukins, growth hormones or other cytokines, hormone therapies, surgery and radiation therapy.
- chemotherapeutic agents such as cytotoxic and cytostatic agents
- immunological modifiers such as interferons and interleukins
- growth hormones or other cytokines hormone therapies, surgery and radiation therapy.
- steroidal progestagens have been proven to be quite safe and are well tolerated. Sometimes, however, side effects (e.g. breast tenderness, headaches, depression, and weight gain) have been reported that are attributed to these steroidal progestagens, either alone or in combination with estrogenic compounds. In addition, steroidal ligands for one receptor often show cross- reactivity with other steroidal receptors. Many steroidal progestagens also bind e.g. to the androgen receptor, whereas many antiprogestagens have affinity for the glucocorticoid receptor.
- Non-steroidal progestagens have no structural similarity with steroids and therefore might be expected to display differential behaviour with respect to physicochemical properties, pharmacokinetic (PK) parameters, or tissue distribution (e.g. CNS versus peripheral), and, more importantly, may show no or less cross-reactivity to other steroid receptors. Therefore, non- steroidal progestagens may be expected to score differently on these aspects and thus offer advantages over steroidal progestagens when applied in therapy.
- PK pharmacokinetic
- the compounds of the present invention show similar agonistic activity in vitro as the compounds from WO 03/084963.
- the particular combination of specific substituents more specifically a nitrile substituent in position 7 in combination with a fluoro substituent in position 8, gives rise to a much enhanced progestagenic activity in vivo, as indicated by the results of the ovulation inhibition assay.
- a high activity i.e., an activity which can be achieved by administering relatively low amounts of compound
- a desirable property for compounds which in therapy may e.g. be administered by the oral route.
- the present invention thus provides compounds which exert a strong progestagenic effect in vivo. More particularly, the present invention relates to (c ⁇ )-8-fluorodibenzo[ ⁇ ,/
- Rl is (l-4C)alkyl, optionally substituted with one or more halogen atoms; and R2 is selected from the group consisting of H, halogen, (l-6C)alkyl, and CN; and R3, R4 and R5 each are independently H or F.
- Rl is CF 3 . In another embodiment, Rl is CH 3 .
- R2 is H. In another embodiment, R2 is Cl and in yet another embodiment R2 is CN.
- R3 is H, in another embodiment R3 is F.
- R4 is H, in another embodiment R4 is F.
- R5 is H, in another embodiment R5 is F.
- R3, R4 and R5 are H.
- R3 is F and both R4 and R5 are H.
- R4 is F and both R3 and R5 are H and in yet another embodiment R5 is F and both R3 and R4 are H.
- Rl is CF 3
- R2 is H
- R3 is H
- R4 is H
- R5 is H
- Rl is CF 3
- R2 is Cl
- R3 is H
- R4 is H
- R5 is H
- the present invention provides compounds useful as intermediates or precursors in preparing the compounds of Formula I where Rl, R3, R4 and R5 have the meaning given previously and where R2 is H.
- These (cis)-8-fluorodibenzo[/ ⁇ /]pyrido[l,2-d]oxazepine-l-amine compounds have general Formula II wherein Rl is (l-4C)alkyl, optionally substituted with one or more halogen atoms.
- the compounds of the subject invention are envisaged for use in therapy.
- the subject invention provides a contraceptive composition comprising a compound of the subject invention and a contraceptively acceptable carrier.
- the subject invention also provides a pharmaceutical composition comprising a compound of the subject invention and a pharmaceutically acceptable carrier.
- a pharmaceutical composition is envisaged for hormone replacement therapy.
- a pharmaceutical composition is envisaged for the treatment of a gynaecological disorder.
- the subject invention furthermore involves a use of a compound of the subject invention for the manufacture of a contraceptive.
- the subject invention also envisages a use of a compound of the subject invention for the manufacture of a medicament.
- a use of a compound of the subject invention is for the manufacture of a medicament for hormone replacement therapy, or, in another embodiment, for the treatment of a gynaecological disorder.
- the subject invention furthermore provides a method of contraception comprising administering a contraceptively effective amount of a compound of the subject invention to an individual in need thereof.
- the subject invention furthermore provides a method of providing hormone replacement therapy comprising administering a pharmaceutically effective amount of a compound of the subject invention to an individual in need thereof.
- the subject invention furthermore provides a method of treating a gynaecological disorder comprising administering a pharmaceutically effective amount of a compound of the subject invention to an individual in need thereof.
- the subject invention provides a compound of Formula II useful in the manufacture of a compound of Formula I, in that compounds of Formula II serve as intermediate in the preparation of compounds of Formula I.
- compounds of Formula II serve as intermediate in the preparation of compounds of Formula I.
- these intermediates of Formula II can be converted to compounds of Formula I by use of CuCN, optionally in the presence of CuI.
- Compounds of Formula II can be prepared as described in WO 03/084963.
- compounds of Formula II can be prepared from compounds of Formula II.
- Another suitable method of resolution is the use of optically pure acids such as tartaric acid or Phencyphos to prepare diastereomerically pure salts of amines of Formula III in which R2 has the meaning as in Formula I.
- Methods to prepare amines of Formula III and the use of these amines to prepare amides of Formula II are described in WO 03/084963.
- (l-4C)alkyl is a branched or unbranched alkyl group having 1, 2, 3 or 4 C atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, and the like;
- (l-6C)alkyl is a branched or unbranched alkyl group having 1, 2, 3, 4, 5, or 6 C atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, sec-pentyl, iso-pentyl, hexyl, sec-hexyl, iso-hexyl and the like;
- Halogen refers to fluorine, chlorine, bromine or iodine;
- laevorotatory when it is found, upon determination of its optical activity, to produce a counter-clockwise rotation of the plane of polarized light.
- dextrorotatory if said rotation of the plane of polarized light is clockwise (Also see R.T. Morrison and R.N. Boyd, Organic Chemistry (3rd Ed). Allyn & Bacon, Boston, 1973, p 119).
- the progestagen receptor affinity and efficacy of the compounds according to the invention make them suitable for use in control of fertility and reproduction, e.g. in female contraception, and further for female HRT, the treatment of gynaecological disorders, as components of male contraception and in diagnostic methods focussed on the amount and/or location of progesterone receptors in various tissues.
- the treatment of gynaecological disorders focussed on the amount and/or location of progesterone receptors in various tissues.
- isotopically labelled variants of the compounds according to the invention it can be preferred to make isotopically labelled variants of the compounds according to the invention.
- the compounds of the invention may further be useful for the treatment of endometriosis, menorrhagia, menometrorrhagia, dysmenorrhoea, acne, fibroids, osteoporosis as well as other bone disorders, bone fraction repair, sarcopenia, frailty, skin ageing, female sexual dysfunction, postmenopausal symptoms, atherosclerosis, aplastic anaemia, lipodystrophy, side effects of chemotherapy, tumours (located in e.g. breast, ovary and uterus) and others.
- Suitable routes of administration for the compounds of the subject invention are oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration or administration via an implant.
- the compounds can be administered orally.
- the exact dose and regimen of administration of the active ingredient, or a contraceptive or pharmaceutical composition thereof, will necessarily be dependent upon the therapeutic effect to be achieved (e.g. contraception, HRT) and may vary with the particular compound, the route of administration, and the age and condition of the individual subject to whom the medicament is to be administered.
- HRT contraception
- a dosage for humans is likely to contain 0.0001-25 mg per kg body weight.
- the desired dose may be presented as one dose or as multiple sub-doses administered at appropriate intervals.
- compositions include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration or administration via an implant.
- the compositions may be prepared by any method well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al., Remington's Pharmaceutical Sciences (18th ed., Mack
- auxiliary agent(s) also named accessory ingredient(s)
- auxiliary agent(s) include those conventional in the art (Gennaro, supra), such as carriers, fillers, binders, diluents, disintegrants, lubricants, colorants, flavouring agents, anti-oxidants, and wetting agents.
- compositions suitable for oral administration may be presented as discrete dosage units such as pills, tablets, dragees or capsules, or as a powder or granules, or as a solution or suspension.
- the active ingredient may also be presented as a bolus or paste.
- the compositions can further be processed into a suppository or enema for rectal administration.
- the invention further includes a contraceptive and a pharmaceutical composition, as hereinbefore described, in combination with packaging material, including instructions for the use of the composition for a use as hereinbefore described.
- compositions include aqueous and non-aqueous sterile injection.
- the compositions may be presented in unit-dose or multi-dose containers, for example sealed vials and ampoules, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of sterile liquid carrier, for example water, prior to use.
- sterile liquid carrier for example water
- transdermal administration e.g. gels, patches or sprays can be contemplated.
- Compositions or formulations suitable for pulmonary administration e.g. by nasal inhalation include fine dusts or mists which may be generated by means of metered dose pressurized aerosols, nebulisers or insufflators.
- the compounds of the invention can also be administered in the form of a vaginal ring such as described for example in EP 876815.
- the compounds of the invention may be administered in conjunction with estrogens, androgens, progestagens, antiprogestagens, and other suitable compounds such as folic acid, vitamins, minerals etc.
- step f from ( ⁇ )-(c ⁇ )-7-bromo-8,14-difluoro-l,3,4,14b- tetrahydro-4-oxo-2H-dibenzo[ ⁇ /
- step i from 2.2 g, (5.77 mmol) of ( ⁇ )-(c ⁇ )-(7-bromo-8,14- difluoro-l,3,4,14b-tetrahydro-2H-dibenzo[ ⁇ ,/
- step 1 from (-)-(c ⁇ )-N-(7-bromo-8,14-difluoro-l,3,4,14b- tetrahydro-2H-dibenzo[ ⁇ /
- step f from ( ⁇ )-(c ⁇ )-7-bromo-8,l l-difluoro-l,3,4,14b- tetrahydro-4-oxo-2H-dibenzo[ ⁇ /
- step k from (-)-(c ⁇ )-7-bromo-8,l l-difluoro-l,3,4,14b- tetrahydro-2H-dibenzo[ ⁇ ,/
- step 1 from (-)-(c ⁇ )-N-(7-bromo-8,l l-difluoro-l,3,4,14b- tetrahydro-2H-dibenzo[ ⁇ ,/
- step 1 from (-)-(c ⁇ )-N-(7-bromo-8,14-difluoro-l,3,4,14b- tetrahydro-2H-dibenzo[ ⁇ /
- Ovulation inhibition after oral administration of the compounds of the invention was studied in mature cyclic rats. Animals were treated with test compound (oral administration) for 1 complete cycle (4 days, from oestrus to pro-oestrus) and the number of ova in the oviduct was microscopically assessed at autopsy in the morning of the next (expected) oestrus. The average number of ova per rat was calculated; the minimal active dose (MAD) is defined as the level at which the average number of ova is reduced by 60% relative to placebo-treated animals. As is evident from Table 1, compounds of the present invention have a much higher activity in vivo.
- Table 1 In vivo progestagenic activity (ovulation inhibition in rat) of 7-cyano-8-fluoro compounds of the present invention and of comparable compounds with different substitution patterns.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT07820620T ATE478078T1 (en) | 2006-09-27 | 2007-09-26 | PYRIDOOXAZEPINE PROGESTERONE RECEPTOR MODULATORS |
AU2007302007A AU2007302007B2 (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesteron receptor modulators |
EP07820620A EP2066677B1 (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesteron receptor modulators |
DK07820620.8T DK2066677T3 (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesterone receptor modulators |
CA002664120A CA2664120A1 (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesteron receptor modulators |
DE602007008589T DE602007008589D1 (en) | 2006-09-27 | 2007-09-26 | PYRIDOOXAZEPIN-PROGESTERONE RECEPTOR MODULATORS |
BRPI0716830-6A BRPI0716830A2 (en) | 2006-09-27 | 2007-09-26 | COMPOUND, COMPOSITION, USE OF A COMPOUND, METHODS OF CONTRACEPTION, HORMONAL REPLACEMENT THERAPY, TREATMENT OF A GYNECOLOGICAL DISORDER, AND TO PRODUCE A COMPOUND |
CN2007800361667A CN101522689B (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesteron receptor modulators |
PL07820620T PL2066677T3 (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesteron receptor modulators |
NZ575276A NZ575276A (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesterone receptor modulators |
JP2009529699A JP2010504943A (en) | 2006-09-27 | 2007-09-26 | Pyridoxazepine progesterone receptor modulator |
SI200730404T SI2066677T1 (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesteron receptor modulators |
MX2009002804A MX2009002804A (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesteron receptor modulators. |
IL197365A IL197365A0 (en) | 2006-09-27 | 2009-03-03 | Pyridooxazepine progesteron receptor modulators |
NO20091016A NO20091016L (en) | 2006-09-27 | 2009-03-06 | Pyridooksazepine-progesterone receptor modulators |
HK09105660.9A HK1126767A1 (en) | 2006-09-27 | 2009-06-24 | Pyridooxazepine progesteron receptor modulators |
HR20100526T HRP20100526T1 (en) | 2006-09-27 | 2010-09-24 | Pyridooxazepine progesteron receptor modulators |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06121372.4 | 2006-09-27 | ||
EP06121372 | 2006-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008037746A1 true WO2008037746A1 (en) | 2008-04-03 |
Family
ID=37813577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/060225 WO2008037746A1 (en) | 2006-09-27 | 2007-09-26 | Pyridooxazepine progesteron receptor modulators |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP2066677B1 (en) |
JP (1) | JP2010504943A (en) |
KR (1) | KR20090064454A (en) |
CN (1) | CN101522689B (en) |
AR (1) | AR063018A1 (en) |
AT (1) | ATE478078T1 (en) |
AU (1) | AU2007302007B2 (en) |
BR (1) | BRPI0716830A2 (en) |
CA (1) | CA2664120A1 (en) |
CL (1) | CL2007002788A1 (en) |
CO (1) | CO6160325A2 (en) |
CY (1) | CY1110846T1 (en) |
DE (1) | DE602007008589D1 (en) |
DK (1) | DK2066677T3 (en) |
ES (1) | ES2349325T3 (en) |
HK (1) | HK1126767A1 (en) |
HR (1) | HRP20100526T1 (en) |
IL (1) | IL197365A0 (en) |
MX (1) | MX2009002804A (en) |
NO (1) | NO20091016L (en) |
NZ (1) | NZ575276A (en) |
PE (1) | PE20071451A1 (en) |
PL (1) | PL2066677T3 (en) |
PT (1) | PT2066677E (en) |
RU (1) | RU2009115643A (en) |
SI (1) | SI2066677T1 (en) |
TW (1) | TW200820975A (en) |
WO (1) | WO2008037746A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7737136B2 (en) | 2002-04-04 | 2010-06-15 | N.V. Organon | Non-steroidal progesterone receptor modulators |
US8063037B2 (en) | 2007-05-07 | 2011-11-22 | N. V. Organon | Progesterone receptor modulators |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101200429B (en) * | 2006-12-13 | 2012-08-22 | 上海睿智化学研究有限公司 | 2-nitro-4,5-dihalogenated phenol and 2-amino-4,5-dihalogenated phenol as well as its salt and method for synthesizing the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003084963A1 (en) * | 2002-04-04 | 2003-10-16 | Akzo Nobel N.V. | Non-steroidal progesterone receptor modulators |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0107179A (en) * | 2000-09-07 | 2002-07-02 | Bayer Ag | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
-
2007
- 2007-09-26 TW TW096135743A patent/TW200820975A/en unknown
- 2007-09-26 WO PCT/EP2007/060225 patent/WO2008037746A1/en active Application Filing
- 2007-09-26 RU RU2009115643/04A patent/RU2009115643A/en not_active Application Discontinuation
- 2007-09-26 NZ NZ575276A patent/NZ575276A/en unknown
- 2007-09-26 DE DE602007008589T patent/DE602007008589D1/en active Active
- 2007-09-26 KR KR1020097007645A patent/KR20090064454A/en not_active Application Discontinuation
- 2007-09-26 DK DK07820620.8T patent/DK2066677T3/en active
- 2007-09-26 MX MX2009002804A patent/MX2009002804A/en not_active Application Discontinuation
- 2007-09-26 PT PT07820620T patent/PT2066677E/en unknown
- 2007-09-26 SI SI200730404T patent/SI2066677T1/en unknown
- 2007-09-26 ES ES07820620T patent/ES2349325T3/en active Active
- 2007-09-26 JP JP2009529699A patent/JP2010504943A/en not_active Ceased
- 2007-09-26 BR BRPI0716830-6A patent/BRPI0716830A2/en not_active IP Right Cessation
- 2007-09-26 AT AT07820620T patent/ATE478078T1/en active
- 2007-09-26 PL PL07820620T patent/PL2066677T3/en unknown
- 2007-09-26 CA CA002664120A patent/CA2664120A1/en not_active Abandoned
- 2007-09-26 EP EP07820620A patent/EP2066677B1/en active Active
- 2007-09-26 CN CN2007800361667A patent/CN101522689B/en not_active Expired - Fee Related
- 2007-09-26 AU AU2007302007A patent/AU2007302007B2/en not_active Ceased
- 2007-09-27 PE PE2007001315A patent/PE20071451A1/en not_active Application Discontinuation
- 2007-09-27 CL CL200702788A patent/CL2007002788A1/en unknown
- 2007-09-27 AR ARP070104267A patent/AR063018A1/en not_active Application Discontinuation
-
2009
- 2009-03-03 IL IL197365A patent/IL197365A0/en unknown
- 2009-03-06 NO NO20091016A patent/NO20091016L/en not_active Application Discontinuation
- 2009-03-27 CO CO09031994A patent/CO6160325A2/en unknown
- 2009-06-24 HK HK09105660.9A patent/HK1126767A1/en not_active IP Right Cessation
-
2010
- 2010-09-24 HR HR20100526T patent/HRP20100526T1/en unknown
- 2010-10-21 CY CY20101100942T patent/CY1110846T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003084963A1 (en) * | 2002-04-04 | 2003-10-16 | Akzo Nobel N.V. | Non-steroidal progesterone receptor modulators |
Non-Patent Citations (1)
Title |
---|
CAULFIELD W L ET AL: "Synthesis of 1-amino-1,2,3,14b-tetrahydro-4H-pyrido[1,2-d]dibenzo[b,f ][1,4]oxazepine and related compounds", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, CHEMICAL SOCIETY. LETCHWORTH, GB, no. 6, 1996, pages 545 - 553, XP002212060, ISSN: 0300-922X * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7737136B2 (en) | 2002-04-04 | 2010-06-15 | N.V. Organon | Non-steroidal progesterone receptor modulators |
US8063037B2 (en) | 2007-05-07 | 2011-11-22 | N. V. Organon | Progesterone receptor modulators |
Also Published As
Publication number | Publication date |
---|---|
EP2066677A1 (en) | 2009-06-10 |
NO20091016L (en) | 2009-03-30 |
DK2066677T3 (en) | 2010-11-08 |
MX2009002804A (en) | 2009-03-31 |
PE20071451A1 (en) | 2008-10-30 |
ATE478078T1 (en) | 2010-09-15 |
AR063018A1 (en) | 2008-12-23 |
RU2009115643A (en) | 2010-11-10 |
KR20090064454A (en) | 2009-06-18 |
CN101522689B (en) | 2012-01-11 |
BRPI0716830A2 (en) | 2013-11-05 |
PL2066677T3 (en) | 2011-02-28 |
NZ575276A (en) | 2011-07-29 |
TW200820975A (en) | 2008-05-16 |
CY1110846T1 (en) | 2015-06-10 |
AU2007302007A1 (en) | 2008-04-03 |
PT2066677E (en) | 2010-11-10 |
JP2010504943A (en) | 2010-02-18 |
CA2664120A1 (en) | 2008-04-03 |
AU2007302007B2 (en) | 2012-02-02 |
IL197365A0 (en) | 2009-12-24 |
SI2066677T1 (en) | 2010-12-31 |
EP2066677B1 (en) | 2010-08-18 |
ES2349325T3 (en) | 2010-12-30 |
HK1126767A1 (en) | 2009-09-11 |
HRP20100526T1 (en) | 2010-11-30 |
CL2007002788A1 (en) | 2008-04-18 |
DE602007008589D1 (en) | 2010-09-30 |
CN101522689A (en) | 2009-09-02 |
CO6160325A2 (en) | 2010-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2435756C2 (en) | Selective androgen receptor modulators | |
TWI555751B (en) | Condensed heterocyclic derivatives of the salt and its crystallization | |
JPH0737460B2 (en) | Pyranoindolizine derivative and method for producing the same | |
JP2012505885A (en) | Methods for synthesizing levodopa ester prodrugs | |
CA2948765A1 (en) | Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds | |
BRPI0620317A2 (en) | acyclically substituted furopyrimidine derivatives, process for preparing and using them and medicament containing said compounds | |
BR112020010837A2 (en) | process for preparing (3s) -3- (4-chloro-3 - {[(2s, 3r) - 2- (4-chlorophenyl) -4,4,4-trifluoro-3-methylbutanoyl] amino} phenyl) - 3-cyclopropylpropanoic and its crystalline form for use as a pharmaceutically active compound | |
EP2066677B1 (en) | Pyridooxazepine progesteron receptor modulators | |
TW201412741A (en) | Process for the preparation of pemetrexed and lysine salt thereof | |
EP1611139B1 (en) | Methods of preparing olanzapine | |
HUT58686A (en) | Process for producing /halogeno-alkyl/-phenyl-alkohols, /halogeno-alkyl/-phenyl-ketones, theyr hydrates and pharmaceutical compositions containing them | |
TW200934774A (en) | Arylmethylidene heterocycles as novel analgesics | |
US8063037B2 (en) | Progesterone receptor modulators | |
US7989442B2 (en) | Progesterone receptor modulators | |
TWI297685B (en) | Non-steroidal progesterone receptor modulators | |
EP2155757B1 (en) | New progesterone receptor modulators | |
WO2021228236A1 (en) | Deuterated tetrahydrothieno[3,4-d]pyrimidinedione compound and pharmaceutical composition comprising compound | |
WO2024099382A1 (en) | Salts and solid forms of a compound having apj receptor activity | |
US20040132765A1 (en) | Clopidogrel salts with alkyl-sulphuric acids | |
KR20020093090A (en) | (5R)-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione | |
KR20230143165A (en) | Benzazepine compounds, methods for their preparation and pharmaceutical uses thereof | |
WO2020206367A1 (en) | Processes for the preparation of deuterated d-serine | |
JPS61233684A (en) | Novel spiroimidazolidine-2,5-dione derivative and production thereof | |
JPH01258680A (en) | 4, 8-dihydro-8-arylisoxazolo (4, 3-e)(1, 4)- oxazepine-5(6h)-one |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780036166.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07820620 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 575276 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007302007 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12009500452 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/002804 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007820620 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2664120 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009529699 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1706/CHENP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09031994 Country of ref document: CO |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007302007 Country of ref document: AU Date of ref document: 20070926 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097007645 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2009115643 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0716830 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090323 |